We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more

Leafly

Shop legal, local weed.

Open
advertise on Leafly
ShopDeliveryDispensariesDealsStrainsBrandsProductsCBDDoctorsCannabis 101Social impact
  • Sign in
  • Create account
  • Strains
  • Shop
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
  • News
  • Lifestyle
  • Strains & products
  • Industry
  • Growing
  • Health
  • Science & tech
  • Leafly USA
  • Podcasts
  • Learn
Politics

Pediatricians Make Recommendation to Decriminalize and Reclassify Cannabis

Lisa RoughPublished on January 27, 2015 · Last updated July 28, 2020

The American Academy of Pediatrics, an influential non-profit medical society, has made the recommendation to the Drug Enforcement Agency that the federal government reclassify cannabis as a non-Schedule I drug so that more research can be conducted on the potential benefits for children with debilitating diseases. They also recommended decriminalization and that doctors advocate for laws that prevent harsh penalties for the use or possession of cannabis.  

The AAP released a policy report recommending that cannabis be decriminalized for minors and young adults and that cannabis be reduced to the list of Schedule 2 drugs, which effectively acknowledges that the substance has been proven to have some medicinal value. By comparison, the Schedule 2 list includes prescribed drugs such as fentanyl and morphine. By removing cannabis from the Schedule I category, this would allow the Federal Drug Administration to conduct further research into the field of pediatrics. 

Only a decade ago, “pediatrics” and “cannabis” would never have been in the same sentence together, but with the increasing evidence of therapeutic benefits for children with epilepsy and seizure disorders, even the most conservative states have been embracing (and legalizing) various versions of extracted cannabinoids.

At the behest of the DEA, the FDA is reviewing marijuana’s status to determine whether the U.S. government should downgrade the classification. This recommendation could have significant implications, depending on whether or not the government decides to listen. Other medical groups have made recommendations in the past, but the tide has been steadily turning in favor of cannabis, and a reclassification would set the stage for a domino effect.

Could the end of prohibition be nigh? #JustSayKnow

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
healthmedical marijuanapediatricsresearch
Lisa Rough
Lisa Rough
Lisa is a former associate editor at Leafly, where she specialized in legislative cannabis policy and industry topics.
View Lisa Rough's articles

The latest in Politics

  • How US import tariffs are impacting cannabis prices and products image
    How US import tariffs are impacting cannabis prices and products
    Leafly Staff
  • Ohioans must activate to defend cannabis freedoms from lawmakers image
    Ohioans must activate to defend cannabis freedoms from lawmakers
    David Downs
  • Montanans must activate to protect legalization in 2025 image
    Montanans must activate to protect legalization in 2025
    David Downs
  • Analysis: Don’t hold your breath for legalization under Trump 2.0 image
    Analysis: Don’t hold your breath for legalization under Trump 2.0
    David Downs
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App StoreDownload Leafly Marijuana Reviews on Google Play

Business Solutions
  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Business log in

About Leafly
  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

Dispensaries in
  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

Privacy & Terms
  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2025 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.